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We monitored cyclooxygenase-2 (COX-2) expression in the insulin-like growth factor-II (IGF-II) treated human
keratinocytes and explored the IGF-II signaling pathways with respect to the expression of COX-2. IGF-II induced
COX-2 mRNA and protein levels, and the up-regulation of COX-2 expression by IGF-II was reduced by pretreatment
with inhibitors of tyrosine kinase, Src and PI3-kinase. The inhibition of extracellular signal-regulated kinase (ERK)
and c-Jun N-terminal kinase (JNK) 1 also reduced the increased expression of COX-2 by IGF-II, but the inhibition of
p38 did not. To further examine the roles of these mitogen-activated protein kinases (MAPKs) in IGF-II-induced
COX-2 expression, we performed COX-2 promoter analysis using dominant negative plasmids of MEK1 (DN-MEK1),
p38 (DN-p38) and JNK1 (DN-JNK1). Although IGF-II increased COX-2 promoter activity approximately 2.5-fold, this
increase was blocked by cotransfection with DN-MEK1 or DN-JNK1. However, DN-p38 did not block the IGF-II-
induced COX-2 promoter activity. In addition, inhibition of ERK or JNK1 reduced the increase of IGF-II-induced
prostaglandin E2 synthesis or cell proliferation. These results suggest that IGF-II induces COX-2 expression
through the tyrosine kinase-Src-ERK and tyrosine kinase-PI3-kinase pathways, but not via p38 MAPK pathway, and
that the basal JNK activity is required for the upregulation of COX-2 by IGF-II, as well.
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Insulin-like growth factor-II (IGF-II), a polypeptide that has a
structural homology with insulin and IGF-I, plays a role in
regulating proliferation and differentiation in a variety of cell
types (Cohick and Clemmons, 1993). A large percentage of
tumors express IGF-II (Singh and Rubin, 1993; Zhang et al,
1997) and IGF-II has also been implicated in various patho-
physiological conditions. In addition, it has been recently
reported that IGF-II was increased in psoriatic lesions, es-
pecially in the serum or blister fluid of psoriasis patients (Xu
et al, 1996). Psoriasis is a chronic disease characterized
by abnormal epidermal proliferation and inflammation. The
proliferation and differentiation of keratinocytes are control-
led by a complex network of growth factors and cytokines
(Luger and Schwarz, 1990). Increased cytokine expres-
sion in inflammatory skin diseases is believed to mediate
the skin inflammatory immune responses and leukocyte
chemotaxis (Nickoloff, 1991, 1999).
Cyclooxygenase-2 (COX-2) is usually expressed at low
or undetectable levels in most tissues and cells, but signif-
icantly in inflammatory cells and other cells by stimuli such
as lipopolysaccharide (LPS), cytokines such as IL-1a, IL-1b
and TNF-a, growth factors, and chemicals (Fu et al, 1990;
Hla et al, 1993; Herschman, 1996; Smith and Dewitt, 1996;
Vane et al, 1998; Wadleigh and Herschman, 1999; Jabbour
et al, 2002; Nakao et al, 2002; Singh and Lucci, 2002; Cho
et al, 2003). COX-2 and its pro-inflammatory products such
as prostaglandin E2 (PGE2) are implicated in the pathogen-
esis of several inflammatory diseases, and selective inhibi-
tion of COX-2 has been shown to be effective in reversing
inflammation in various tissues without gastric side effects
(Crofford et al, 1994; Masferrer et al, 1994; Smith and De-
witt, 1996; Vane et al, 1998). In addition to its association
with inflammation, COX-2 expression clearly plays a role in
regulating cellular proliferation, differentiation, and tumori-
genesis (Bornfeldt et al, 1997), which are supported by the
recent data from COX-2 transgenic and COX-2 knockout
studies. Knockingout COX-2 curtailed the 12-O-tetrad-
ecanoylphorbol-13-acetate-induced hyperplasia that was
caused by an accelerated terminal differentiation (Tiano
et al, 2002). Constitutive COX-2 overexpression in basal
epidermal keratinocytes induced an autopromoted pheno-
type in dorsal epidermis and sensitized the tissue for geno-
toxic carcinogens (Muller-Decker et al, 2002). In addition,
Neufang et al (2001) reported that constitutive COX-2 over-
expression in tail skin caused hyperplasia, due to a delay of
terminal differentiation rather than to a stimulation of cell
proliferation. COX-2, as an inflammatory mediator, also has
recently been found to be involved in angiogenesis (Cianchi
et al, 2001; Gallo et al, 2002; Kirkpatrick et al, 2002) and to
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be overexpressed in the synovial fluid of patients with
psoriatic arthritis (Iniguez et al, 1998).
It is believed that IGF-II plays a role in the pathogenesis
of skin disorder by regulating the expression of angiogenic
factors and inflammation mediators. However, The specific
molecular function of IGF-II in promoting angiogenesis and
the inflammatory response remains to be investigated.
Therefore, in this study, we attempted to examine the ef-
fects of IGF-II on the expression of COX-2 gene encoding
the inflammatory factor in human keratinocytes. Moreover,
the mechanism by which IGF-II regulates the expression of
this gene in human keratinocyte was further investigated.
Results
Induction of COX-2 genes by exogenous IGF-II in the
primary normal human keratinocytes and HaCaT cells
Since it has been reported that IGF-II was overexpressed in
the inflammatory skin diseases such as psoriasis, and COX-
2 was also implicated in the pathogenesis of several in-
flammatory diseases we hypothesized that IGF-II may affect
the cell proliferation and the inflammatory response by in-
ducing the expression of the COX-2. In order to investigate
whether IGF-II is able to increase the COX-2 expression
levels in the primary normal human keratinocytes and the
immortalized human keratinocyte cell line, HaCaT, the pri-
mary normal human keratinocytes was treated with ex-
ogenous IGF-II (100 ng per mL) and the COX-2 mRNA levels
were increased 0.5, 1, 2, and 4 h after treatment (Fig 1A).
Production of the COX-2 protein was monitored in a time
course following IGF-II treatment and reached the maxi-
mum level at 16 h after the IGF-II treatment (Fig 1A) in nor-
mal keratinocytes. When the HaCaT cells were treated with
IGF-II (100 ng per mL), northern blot analyses showed that
the COX-2 mRNA level was significantly increased time de-
pendently and reached the maximum level at 8 h after the
IGF-II treatment (Fig 1B). The COX-2 protein level was also
increased in a time-dependent manner, and reached the
maximum level at 16 h after the IGF-II treatment.
COX-2 expression mediated by IGF-II is implicated in
tyrosine kinase and the subsequent pathway (Src-PI3-
kinase pathway) There are some reports on the different
response between normal primary keratinocytes and Ha-
CaT (Weninger et al, 1998; Mildner et al, 1999), in which p53
is mutated and abnormally overexpressed compared with
primary keratinocytes. HaCaTexhibits, however, most of the
characteristics of the basal keratinocytes (Wraight et al,
1994; Wraight and Werther, 1995), and importantly, it ex-
hibits hyperproliferation that is typical of epidermal keratin-
ocytes in psoriatic lesion (Bonnekoh et al, 1991). Therefore,
we investigated the COX-2 expression in IGF-II-treated hu-
man keratinocytes and explored the signaling pathways of
COX-2 expression by IGF-II in HaCaT.
The effects of IGF-II on keratinocyte cells are exerted by
its interaction with the three major cell surface receptors,
insulin receptor, IGF-I receptor, and IGF-II receptor. Of
them, insulin receptor and IGF-I receptor have an intrinsic
tyrosine kinase activity (Storchenfeldt et al, 1991). IGF-II-
associated receptor tyrosine kinases were investigated to
determine if they are directly involved in the COX-2 expres-
sion caused by IGF-II in the mRNA level at 8 h and protein
level at 16 h after the IGF-II treatment. When the HaCaT
cells were pre-treated with a tyrosine kinase inhibitor, Geni-
stein, for 1 h prior to the IGF-II treatment, the induction of
COX-2 mediated by IGF-II was decreased (Fig 2A,B).
Then, we investigated the possibility that the IGF-II-me-
diated activation of the receptor tyrosine kinases elicits the
phosphorylation of Src and PI3-kinase, thereby altering the
COX-2 expression. Pre-treatment of the cells with the Src
inhibitor, PP1, and the PI3-kinase inhibitor, LY294002, sig-
nificantly decreased the IGF-II-induced COX-2 mRNA and
protein expression, respectively (Fig 2A,B). These results
suggest that IGF-II induces COX-2 expression by mediating
the activation of the receptor tyrosine kinases, which elicit
the phosphorylation of Src and PI3-kinase.
The mitogen-activated protein kinase (MAPK) pathway
is differentially involved in the IGF-II-mediated overex-
pression of the COX-2 gene in HaCaT cells One of the
most extensively investigated intracellular signaling cas-
cades involved in pro-inflammatory responses is the MAPK
pathway. There are accumulating evidences indicating that
Figure1
Induction of cyclooxygenase-2 (COX-2) genes by exogenous in-
sulin-like growth factor-II (IGF-II). Primary normal human keratin-
ocyte (A) and HaCaT (B) cells. Northern blot analyses for COX-2 mRNA
levels and western blot analyses for COX-2 protein levels were per-
formed in a time-dependent manner. The COX-2 mRNA levels were
detected in the total RNA fractions (35 mg per lane) isolated from the
cells. The amount of RNA loaded in each lane was confirmed by re-
hybridization of the stripped membrane with a 32P-labeled probe com-
plementary to GAPDH RNA. Immunoblot analysis for the COX-2 protein
was performed, time dependently, with the extract from the IGF-II (100
ng per mL)-treated cells. The detailed procedure is described in Ma-
terials and Methods. Briefly, 20 g of the total protein for COX-2 were
electrophoresed on 8% polyacrylamide gels. The cells were incubated
with the goat polyclonal COX-2 antibody, diluted by 1:500 in TBST
containing 5% bovine serum albumin (BSA) for 2 h, and then incubated
with the secondary antibodies at room temperature for 1 h. Anti-goat
antibodies for COX-2 were used as the secondary antibodies (1:5000
dilution in TBST containing 1% BSA). The data were confirmed by two
independent experiments.
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enzymes of the MAPK family play a role in COX-2 gene
expression (Hwang et al, 1997; Pouliot et al, 1997; Dean
et al, 1999). We further investigated the signal transduction
pathway, which mediates the increased COX-2 expression
by IGF-II. COX-2 overexpression in the mRNA and protein
levels after IGF-II treatment was significantly diminished
following addition of the specific extracellular signal-regu-
lated kinase (ERK) inhibitor, PD98059 (40 mM). In contrast,
pre-treatment with the P38 inhibitor, SB203580 (5 mM), did
not moderate the IGF-II-induced COX-2 expression (Fig
3A,B). SP600125 known as a novel specific inhibitor of c-
jun N-terminal kinase (JNK)1, 2, and 3 (Bennett et al, 2001)
did not block the IGF-II-induced COX-2 expression and
rather increased the COX-2 expression by IGF-II in a con-
centration-dependent manner (5–100 mM) in HaCaT (data
not shown). It has been reported that hypertonicity selec-
tively activates JNK-2, but not the other isoforms of JNK,
and that hypertonicity-stimulated COX-2 is reduced only in
dominant-negative JNK2 mutant (DN-JNK2)-expressing
cells, but not in DN-JNK1- and DN-JNK3-expressing cells
(Wojtaszek et al, 1998; Yang et al, 2000). These data may
support the possibility that isoforms of JNK differentially
regulate the IGF-II-induced COX-2 expression. In addition,
SP600125 appears to affect the unknown pathway involved
in the expression of COX-2 by IGF-II at high concentration in
HaCaT. To rule out this possibility, we investigated the role
of JNK1 on the IGF-II-induced COX-2 expression using DN-
JNK1. IGF-II-induced COX-2 expressions were reduced by
overexpression of DN-JNK1 in mRNA and protein levels.
This indicates that the induction mechanism of COX-2 by
IGF-II is differentially implicated in the MAPK pathway. Of
them, ERK and JNK1, but not p38, are involved in the IGF-
II-mediated overexpression of the COX-2 gene.
The activation of MAPK by IGF-II Treatment with various
kinase inhibitors and dominant-negative mutant showed that
upregulation of COX-2 by IGF-II occurs through the ERK and
JNK1 pathway. We further examined whether IGF-II indeed
facilitates phosphorylation of ERK, p38, or JNK. Results
showed that phosphorylation of ERK1/2 started to be de-
tected at 1 h after IGF-II treatment, peaked at 4 h, and
decreased thereafter (Fig 4A). Phospho-p38 was also
increased by IGF-II treatment, as was total p38 (Fig 4B).
Thus it is not likely that phospho-p38 is involved in the gene
regulation by IGF-II. The phosphorylation level of JNK (p54/
p46), however, was not affected significantly at any time
point (Fig 4C). This figure also shows that the basal level of
p-JNK (p46) is relatively high in HaCaT cells. These results
suggest that the ERK is mainly involved in the COX-2 gene
expression by IGF-II. The fact that the DN-JNK1 inhibited the
effect of IGF-II, although IGF-II dose not increase the phos-
phorylation of JNK, suggests that the basal JNK activity
is required for the stimulating effect of IGF-II on COX-2
expression, whereas DN-JNK1 reduced slightly the basal
level of p-JNK but not p-JNK by IGF-II. Pre-incubation of
cells with PD98059 or SB203580 inhibited the IGF-II-induced
Figure 2
Cyclooxygenase-2 (COX-2) expression mediated by insulin-like growth factor-II (IGF-II) is implicated in tyrosine kinase and the subsequent
pathway (Src-PI3-kinase pathway). (A) Northern blot analysis for COX-2 mRNA and the relative COX-2 mRNA levels. The COX-2 mRNA levels were
detected in the total RNA fractions (35 mg per lane). The HaCaT cells were incubated for 1 h with the tyrosine inhibitor, Genistein (GT; 20, 50, and 100
mM), the Src inhibitor (PP1; 2, 5, and 10 mM), and the PI3-kinase inhibitor (LY294002; 5, 10, and 20 mM). IGF-II (100 ng per mL) was then added to the
cells. Eight hours later, the total RNA was extracted from the cells and northern blot analyses were done. (B) Immunoblot analysis for the COX-2
protein and the relative COX-2 protein levels. The confluent HaCaT cells were treated with IGF-II (100 ng per mL) and the total cell lysate was
extracted from the cells after 16 h of IGF-II treatment. Western blot analysis was performed as shown in Fig 1. The inhibitors were pretreated for 1 h
before IGF-II treatment. The band intensities were assessed by scanning densitometry. The data are presented as the mean  SEM of three
independent experiments. One-way analysis of variance was used to compare the multiple group means followed by Newman–Keuls test (sig-
nificance compared with the control, po0.01; significance compared with IGF-II, wwpo0.01) (control level¼1).
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phosphorylation of ERK1/2 or p38, indicating that these in-
hibitors are blocking their target pathways as predicted.
Upregulation of COX-2 promoter activity by IGF-II
through an ERK and JNK-dependent pathway To further
determine the role of MAPK involved in IGF-II-induced
COX-2 expression, we performed luciferase reporter gene
assay. HaCaT cells were transiently co-transfected with
COX-2 promoter-luciferase reporter and expression vectors
encoding dominant-negative MEK1 mutant (DN-MEK1),
dominant-negative p38 mutant (DN-p38), or DN-JNK1. The
˙
transfected cells were stimulated with IGF-II for 16 h, and
Figure 3
Mitogen-activated protein kinase (MAPK) differentially involves in insulin-like growth factor-II (IGF-II)-induced cyclooxygenase-2 (COX-2)
gene expression. (A) Northern blot analysis for COX-2 mRNA and the relative COX-2 mRNA levels. The HaCaTcells were treated with IGF-II (100 ng
per mL) for 8 h after a preincubation for 1 h with the ERK inhibitor (PD98059; 10, 20, and 40 mM) and the P38 inhibitor (SB203580; 5 mM), or
overexpression of dominant-negative JNK1 mutant (DN-JNK1). (B) Immunoblot analyses for the COX-2 protein and the relative COX-2 protein levels.
The COX-2 protein expression level was measured from the cells treated with IGF-II (100 ng per mL) for 16 h after a pretreatment with PD98059 (10,
20, and 40 mM) and SB203580 (1, 3, and 5 mM) or overexpression of DN-JNK1. Scanning densitometry was used to assess the relative COX-2 mRNA
and protein levels. The data are presented as the mean  SEM of three independent experiments. One-way analysis of variance was used to
compare the multiple group means followed by Newman–Keuls test (significance compared with the control, po0.01; significance compared with
IGF-II, wwpo0.01) (control level¼ 1).
Figure4
Insulin-like growth factor-II (IGF-II) phos-
phorylates mitogen-activated protein kin-
ase (MAPK). The cell lysate was extracted
from the cells treated with IGF-II (100 ng per
mL) at the indicated times and then immuno-
blot analysis was performed using anti-p-
ERK1/2 and anti-ERK1/2 (A), anti-p-p38 and
anti-p38 (B), or anti-p-SAPK/JNK (p54/p46)
and anti-SAPK/JNK antibodies (Thr183/
Tyr185) (C). To determine the specificity of
the MAPK inhibitors, HaCaT cells were pre-
incubated for 1 h with ERK inhibitor PD98059
and p38 inhibitor SB203580, or transfected
with dominant-negative JNK1 mutant (DN-
JNK1). Each lane was loaded with 80 mg of
the cell lysates. The data were confirmed by
two experiments.
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then luciferase activity was measured. As shown in Fig 5A,
IGF-II increased COX-2 promoter-luciferase activity by ap-
proximately 2.7-fold compared with that from the untreated
control. IGF-II-induced COX-2 promoter-luciferase activity
was substantially reduced by overexpression of DN-MEK1
(Fig 5B) and DN-JNK1 (Fig 5D). In contrast, overexpression
of DN-p38 did not inhibit IGF-II-induced COX-2 promoter-
luciferase activity (Fig 5C). These results demonstrate that
ERK and JNK pathways contribute to IGF-II-induced COX-2
expression.
Inhibition of the ERK and JNK1 pathway decreased IGF-
II-induced PGE2 synthesis or cell proliferation We
showed that IGF-II-induced COX-2 gene expression in the
mRNA and protein levels through the tyrosine kinase-Src-
PI3-kinase and the tyrosine kinase-Src-ERK or -JNK1 path-
way. We also investigated whether the increase of COX-2
gene levels was associated with PGE2 synthesis or cell pro-
liferation. To analyze the effect of IGF-II on PGE2 synthesis or
cell proliferation, we performed ELISA assay to quantify the
PGE2 synthesis and [
3H]thymidine uptake experiments for
proliferation. As shown in Fig 6A, PGE2 synthesis was in-
creased approximately 1.5-fold by IGF-II treatment for 24 h.
This increase was blocked by pre-treatment with Genistein,
PP1, LY294002, and PD98059 or by overexpression of DN-
JNK1, but not by SB203580. The induction of COX-2 ex-
pression by IGF-II also facilitated the proliferation of HaCaT
via the tyrosine kinase-Src-PI3-kinase and the tyrosine kin-
ase-Src-ERK or -JNK1 pathway (Fig 6B).
Discussion
IGF are important mitogens in many normal and patholog-
ical systems. IGF are essential for normal embryonic post-
natal growth (Murphy et al, 1987; Han et al, 1988), and their
overexpression is frequently observed in hyperproliferative
states that occur in human cancers of the prostate, breast,
and liver as well as psoriasis (Osborne et al, 1989; D’Errico
et al, 1994; Tennant et al, 1996; Xu et al, 1996). IGF-II ex-
erted its effect on the cells by its interaction with the insulin
receptor or the IGF-I receptor. Both the insulin receptor and
the IGF-I receptor are expressed in the keratinocytes (Ver-
rando and Ortonne, 1985; Misra et al, 1986; Hodak et al,
1996). Krane et al (1992) reported that IGF-I receptor ex-
pression is increased in psoriasis as measured by protein
tyrosine kinase assays of tissue extracts and by immuno-
histochemical staining with an IGF-I receptor specific
monoclonal antibody. Moreover, Wraight et al (2000) report-
ed that inhibition of the IGF-I receptor expression in a
psoriatic lesion reversed the psoriatic epidermal hyperplasia
by slowing the rate of keratinocyte cell division. This sug-
gests that IGF-I receptor stimulation is a rate-limiting step in
psoriatic epidermal hyperplasia.
The insulin receptor protein family is a widely expressed
tyrosine kinase family that mediates insulin and IGF-I
signaling (Taylor, 1992; Van Obberghen, 1994; Cheatham
and Kahn, 1995). It was reported that the activated insulin
and IGF-I receptors phosphorylate the Src homology/col-
lagen (SHC) proteins in vitro, and that the expression of
the exogenous SHC proteins results in increased basal
Figure 5
Insulin-like growth factor-II (IGF-II) induces cyclooxygenase-2 (COX-2) promoter activity through an extracellular signal-regulated kinase-
or c-Jun N-terminal kinase (JNK)1-dependent signaling pathway. HaCaT cells were transiently co-transfected with empty vector or COX-2
promoter-luciferaseþpRL-TK-luciferase (A), empty vector or plasmids encoding dominant-negative MEK1 mutant (DN-MEK1) and COX-2 pro-
moter-luciferaseþpRL-TK-luciferase (B), empty vector or dominant-negative p38 mutant (DN-p38) and COX-2 promoter-luciferaseþpRL-TK-
luciferase (C), and empty vector or dominant-negative JNK1 mutant (DN-JNK1) and COX-2 promoter-luciferaseþpRL-TK-luciferase (D). Transfected
cells were washed and then incubated in serum-free media for 24 h to allow expression of DN-MEK1, DN-p38, or DN-JNK1. Cells were stimulated
with IGF-II (100 ng per mL) for 16 h. Luciferase activities are presented as fold activation relative to those of the untreated cells. The data are
presented as the mean  SD of three independent experiments. One-way analysis of variance was used to compare the multiple group means
followed by Newman–Keuls test (significance compared with the control, po0.05; significance compared with IGF-II, wwpo0.01) (control level¼ 1).
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MEK (MAPK/ERK-activating kinase) activity (Giorgetti et al,
1994). MAPK pathways are strongly involved in many
processes in immune response and pro-inflammatory re-
sponse. Therefore it is likely that the elevated IGF-II levels
may play an important role in the inflammatory diseases
such as psoriasis. Nevertheless, the precise signaling
pathway by which IGF-II regulates the expression of the
inflammation-related genes such as COX-2 in human ker-
atinocyte is unclear. In this study, we demonstrated for the
first time the IGF-II-induced expression of COX-2 by phos-
phorylating tyrosine kinase, Src, and PI3-kinase, followed
by activation of the ERK pathway in the HaCaT cells. The
increase in the level of COX-2 protein by IGF-II is probably
responsible for the observed increase in PGE2 synthesis
and cell proliferation. These results suggest that IGF-II may
affect the inflammation, hyperproliferation, or angiogenesis
of psoriasis by regulating the expression of the inflamma-
tory factor, COX-2 and its pro-inflammatory products,
PGE2. It is supported by the previous report that COX-2 is
overexpressed in the synovial fluid of patients with psoria-
tic arthritis (Iniguez et al, 1998).
In addition, we found that HaCaT showed the high basal
level of JNK activity and the basal JNK activity was re-
quired for the expression of COX-2 by IGF-II. Ramaswamy
and Pelling (1999) reported the modulation of the JNK1
pathway by the wild-type or mutant status of the p53
gene’s protein product. They have reported that A1-5 rat
fibroblast cell line expressing p53 protein predominantly in
the mutant conformation exhibited a significantly higher
basal level of JNK1 activity than cells expressing wild-type
p53 protein. It has also been reported that the presence of
mutant p53 protein in cells was accompanied by a signif-
icant reduction in the ability of cells to induce JNK1 activity
above the basal level in response to UVB or UVC irradi-
ation. These findings supported that HaCaT, in which p53
is mutated and abnormally overexpressed, showed the
high level of basal JNK activity and, thus, JNK activity was
not affected by IGF-II.
Previous studies have demonstrated that depending on
the type of cell, stimuli and species, each MAPK has a dif-
ferent regulatory role in COX-2 gene expression. JNK plays a
critical regulatory role in human COX-2 transcription in ma-
crophages activated by human herpesvirus 6 (Janelle et al,
2002) or LPS (Wadleigh et al, 2000), and in murine MC3T3-
E1 osteogenic cells stimulated with PGE2 or TNF-a plus IL-
1b (Wadleigh and Herschman, 1999). In contrast, LPS-in-
duced murine COX-2 promoter activity in RAW264.7 cells is
dependent on ERK (Wadleigh et al, 2000). Both ERK and
JNK are required for COX-2 promoter activity induced by IgE
receptor aggregation in mast cells (Billack et al, 2002).
ERK1/2 and p38 play a role in regulating HSP60-induced
expression of COX-2 in macrophages (Billack et al, 2002). In
this study, we determined the differential role of MAPK in the
IGF-II-induced COX-2 expression in HaCaT. ERK and JNK1
played a critical role in the IGF-II-induced COX-2 promoter
activity in human keratinocyte, but p38 did not.
In addition, we might suggest that the activation of tran-
scription factors nuclear factor-kB (NF-kB) and AP-1 plays a
role in the IGF-induced COX-2 expression. The COX-2 gene
contains binding sites for a number of important transcrip-
tion factors, including NF-kB and AP-1 (Appleby et al, 1994).
Increases in NF-kB-DNA or AP-1-DNA binding immediately
precede upregulation of COX-2 gene transcription in vari-
ous cell lines (Newton et al, 1997a, b; Guo et al, 2001; Sub-
baramaiah et al, 2001; 2002). It has been recently reported
that IGF-II induces NF-kB activation (Kaliman et al, 1999;
Kwon et al, 2000) in agreement with our own data (Kim et al,
2004). In addition, IGF-II-treated HaCaT cells showed the
activation of AP-1 (Kim et al, 2004). IGF-II-activated NF-kB
and AP-1 also may be involved in COX-2 expression.
Therefore, it is plausible that IGF-II induces COX-2 expres-
sion through not only NF-kB activation, but also through
other transcription factors including AP-1 in keratinocyte.
Figure 6
Inhibition of the extracellular signal-regulated kinase (ERK) and
c-Jun N-terminal kinase (JNK)1 pathway decreased insulin-like
growth factor-II (IGF-II)-induced prostaglandin E2 (PGE2) synthesis
or cell proliferation. (A) The PGE2 ELISA assay was performed using
the supernatant from the IGF-II-treated HaCaT at 24 h after treatment.
The inhibitors were pretreated for 1 h before IGF-II treatment.
Transfections with dominant-negative JNK1 mutant (DN-JNK1) mutant
were allowed to proceed for 24 h prior to IGF-II treatment. The data are
presented as the mean  SEM of three independent experiments.
One-way analysis of variance was used to compare the multiple group
means followed by Newman–Keuls test (significance compared with
the control, po0.05 or po0.01; significance compared with IGF-II,
wpo0.05) (control level¼ 1). (B) Cells were pretreated with the inhibitors
for 1 h or transfected with DN-JNK1 mutant 24 h prior to, and then were
stimulated with IGF-II (100 ng per mL) for 24 h. The incorporation of
3[H]thymidine into the trichloroacetic acid-insoluble cellular fraction
was determined. The data were normalized to the extent of 3[H]thymi-
dine incorporation observed in unstimulated cells. The data are pre-
sented as the mean  SEM of three independent experiments. One-
way analysis of variance was used to compare the multiple group
means followed by Newman–Keuls test (significance compared with
the control, po0.01; significance compared with IGF-II, wwpo0.01)
(control level¼1).
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In conclusion, our results suggest that IGF-II induces the
expression of inflammatory factors such as COX-2, which
may be involved in the pathogenesis of psoriasis, through
the tyrosine kinase-Src-ERK and tyrosine kinase-PI3-kinase
pathways and that the basal JNK activity are required for
upregulation of COX-2 by IGF-II.
Materials and Methods
Materials Dulbecco’s modified Eagle’s medium (DMEM), fetal
bovine serum (FBS), and antibiotics (penicillin/streptomycin)
were obtained from Gibco-BRL (Rockville, Maryland). Anti-COX-2
and anti-b-tubulin antibodies were purchased from Santa Cruz
(Santa Cruz Biotechnology, California), and anti-p-MAPK (p-p44/42
(ERK1/2), p-p38 or p-SAPK/JNK) and anti-MAPK (p44/42 (ERK1/
2), p38, SAPK/JNK) antibodies from Cell Signaling Technology
(Beverly, Maryland). [a-32P]dCTP (3000 mCi per mmol) was pur-
chased from Amersham Pharmacia Biotech (Piscataway, New Jer-
sey), recombinant human IGF-II from R&D Systems (Minneapolis,
Minnesota), Genistein from Alexis (San Diego, California), PP1
from Biomol (Plymouth Meeting, Pennsylvania), and SB203580,
PD98059, and SP600125 from Calbiochem (San Diego, California).
All other chemicals including LY294002 and anti-actin antibodies
were purchased from Sigma Chemicals (St Louis, Missouri).
Primary cell culture The normal human epidermal keratinocyte
was obtained from Welskin (Seoul, Korea). The normal human ep-
idermal keratinocyte was maintained in keratinocyte basal medium
(KBM; Clonetics Corp., Walkersville, MD) containing 5  107 M
hydrocortisone, 5 ng per mL of an epidermal growth factor, 30 mg
per mL of a bovine pituitary extract, 5 mg per mL insulin, 50 mg per
mL gentamicin, and 50 ng per mL amphotericin B. The culture was
maintained in a humidified atmosphere of 5% CO2 in air at 371C.
Generally, after 2–3 d, small clusters of adherent cells were ap-
parent and the KBM was changed every 2–3 d with the subsequent
appearance of progressively larger keratinocyte colonies. The cells
were starved with supplement-free KBM for 24 h before addition of
IGF-II.
Cell culture The immortalized human keratinocyte cell line, Ha-
CaT, was kindly provided by Professor N. Fusenig (German Cancer
Research, Germany). Cells were maintained as monolayer cultures
in DMEM supplemented with 10% FBS, 100 U per mL penicillin,
and 100 mg per mL streptomycin at 371C in humidified atmosphere
with 5% CO2. The cells were seeded at a density of 1  106 cells
per 100 mm dishes. After 48 h, the cells were washed with serum-
free medium, and then replaced with media without FBS at least
24 h prior to experiments for treatment.
Treatment of cells with inhibitors Cells were pre-treated with
either LY294002 (an inhibitor of PI3-kinase), PD98059 (a selective
ERK inhibitor), SB203580 (a p38 inhibitor), SP600125 (a selective
JNK inhibitor), PP1 (an Src family specific inhibitor), or Genistein (a
tyrosine kinase inhibitor) for 1 h in serum-free medium (Table I).
IGF-II (100 ng per mL) was then added to the cells.
Preparation of total RNA and northern blot hybridization The
total RNA was isolated from the cells treated with IGF-II according to
the single step guanidine thiocyanate–phenol–chloroform extraction
procedure using Trizol (Invitrogen, Carlsbad, California) in line with
the manufacturer’s instructions. The total RNA (35 mg) was elect-
rophoresed in a 1% agarose gel containing 2.2 M of formaldehyde,
transferred to a nylon membrane (Osmonics, Westborough, Massa-
chusetts), and covalently linked by UV cross-linker (UV Stratalinker
1800; Stratagene, La Jolla, CA). Hybridization was performed with
32P-labeled cDNA probe prepared by random primer oligonucleo-
tides (Rediprime DNA Labeling System; Amersham).
Immunochemistry analysis The cells were harvested and lysed
with buffer containing 0.5% SDS, 1% NP-40, 1% sodium de-
oxycholate, 150 mM NaCl, 50 mM Tris-Cl (pH 7.5) and protease
inhibitors. The protein concentration of each sample was deter-
mined using a BCA protein assay kit (Pierce, Rockford, Illinois).
Twenty micrograms of the total protein for COX-2 detection
were electrophoresed on 8% polyacrylamide gels and 80 mg for
phospho-MAPK detection on 12% polyacrylamide gels, and trans-
ferred to nitrocellulose membranes by a semi-dry electrophoretic
transfer on a Bio-Rad TransBlot SD apparatus (Bio Rad, Hercules,
CA) at 15 V for 60–75 min. The nitrocellulose membranes were
blocked overnight at 41C in 5% bovine serum albumin (BSA). The
cells were incubated with the primary antibodies, diluted by 1:500
in TBST containing 5% BSA for 2 h, followed by incubation with the
secondary antibodies at room temperature for 1 h. Anti-COX-2,
anti-p-p44/42 MAPK (p-ERK1/2), anti-p-44/42 MAPK (ERK1/2),
anti-p-p38 MAPK, anti-p38 MAPK, anti-p-SAPK/JNK (Thr183/
Tyr185) or anti-SAPK/JNK antibody was used as a primary anti-
body. HRP-conjugated anti-goat for COX-2 or anti-rabbit IgG for
p-ERK1/2, p-p38 and p-SAPK/JNK was used as a secondary
antibody (1:5000 dilutions in TBST containing 1% BSA). The sig-
nals were detected by ECL (Amersham Pharmacia Biotech).
Quantitative human PGE2 immunoassay The quantity of PGE2
secreted into the culture medium was analyzed using a Quantikine
human PGE2 chemiluminescence kit (R&D Systems), according to
the manufacturer’s manual, for quantitative and specific sandwich
enzyme immunoassay. Both the samples and standards were as-
sayed in parallel.
[3H]Thymidine uptake experiments The cells were seeded in 96-
well plates (3  103 cell per well) in DMEM. After 2 d of incubation,
the cells were then serum starved in serum-free DMEM for another
24 h. Cells were then simultaneously treated with 100 ng per mL
IGF-II for 24 h, after which 0.5 mCi of [3H]thymidine (85 Ci per mmol)
was added to each well, and cells were further incubated for 1 h
at 371C. Cells in wells were washed twice with ice-cold PBS,
extracted with 5% trichloroacetic acid, and solubilized in 0.1 M
NaOH. Trichloroacetic acid-insoluble radioactivity was measured
by scintillation counting.
Plasmid Construction of the specific regions (1917/þ 127) of the
human COX-2 gene promoter in the luciferase reported pGL3 Ba-
sic (Promega, Madison, Wisconsin) was accomplished by PCR
Table I. Specific inhibitors for signaling pathway
Target Molecule Concentration (lM) Reference
Tyrosine kinase Genistein 25–100 Akiyama et al (1987), Gradin et al (1994)
Src PP1 2–10 Klint et al (1999), Mariotti et al (2001)
PI3-kinase LY294002 5–20 Yao and Cooper (1995), Dong et al (2001)
ERK PD98059 10–40 Servant et al (1996), Ghosh et al (2002), Kaufmann and Thiel (2002), Buckley et al (1999)
p38 SB203580 1–5 McLaughlin et al (1996), Cheng et al (2002), Rosenberger et al (1999), Shimizu et al (1999)
JNK SP600125 5–100 Bennett et al (2001)
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amplification. The DN-MEK1 plasmid pUSE-DN-MEK1, the DN-
p38 plasmid pEF6-DN-p38, the DN-JNK1 plasmid pCDNA3-
DN-JNK1 and the control vector were kindly provided by
Dr A.-K. Yi (University of Tennessee Health Science Center, Mem-
phis, Tennessee).
Transfections Transient transfections were performed using Lip-
ofectin (Gibco-BRL) according to the manufacturer’s protocol.
Briefly, 5  105 cells were plated in 60 mm dish plate the day be-
fore transfection and grown to about 70% confluence. Two mi-
crograms per plate of plasmid DNA prepared by Qiagen kit
(Qiagen, Santa Clara, California) were transfected. Transfections
were allowed to proceed for 24 h. The transfected cells were
washed with 4 mL of PBS and then stimulated with IGF-II (100 ng
per mL). The cells were continually cultured in serum-free DMEM
until the cells were harvested. Transfection efficiency was correct-
ed by co-transfection of 0.5 mg of phRL-TK Vector (Promega).
Luciferase assay After experimental treatments, cells were
washed twice with cold PBS, lysed in passive lysis buffer provid-
ed in the dual luciferase kit (Promega) and assayed for luciferase
activity using a TD-20/20 luminometer (Turner Designs, Sunnyvale,
California) according to the manufacturer’s protocol. All transfect-
ions were done in triplicate. The data were presented as a ratio
between Firefly and Renilla luciferase activity.
Data analysis Scanning densitometry was performed using an
Image Masters VDS (Pharmacia Biotech Inc., San Francisco, Cal-
ifornia). The one-way analysis of variance procedure was used to
assess the significant differences among the treatment groups. For
each significant effect of treatment, the Newman–Keuls test was
used for significance set at po0.05 or po0.01.
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